Flash News

TREE NEWS update: Irish police seized an improvised explosive device on 13 March close to the venue where leaders of several countries had held a dinner the previous day. Army bomb disposal experts were called in and safely dealt with the device, described as crudely made but capable of detonation.

TREE NEWS update: China’s domestically developed 10-tonne electric commercial aircraft CE-25A completed its first crewed intelligent flight in Binzhou, Shandong on November 14, carrying two pilots and one flight-test engineer. The aircraft performed normally with all indicators meeting expectations. The flight follows the CE-25A’s uncrewed intelligent maiden flight on February 2 this year.

TREE NEWS update: Canadian Prime Minister Mark Carney said Canada and the Philippines have concluded negotiations on a free trade agreement, with both sides aiming to bring the pact into force next year. The announcement marks the end of the negotiation phase; the agreement is targeted to take effect in 2026.

TREE NEWS update: China Securities Regulatory Commission Chairman Wu Qing said the regulator will deepen research into two-way empowerment between artificial intelligence and capital markets, speaking at the 2026 China Capital Market Academic Annual Conference. Wu said the CSRC will study valuation and pricing, disclosure rules and liability determination, data security, client protection and systemic risk, with a focus on guarding against algorithm black boxes, AI cyberattacks and improving the resilience of financial infrastructure to promote safe and standardized AI application.

TREE NEWS update: China Securities Regulatory Commission Chairman Wu Qing said the regulator will step up research on how listing rules can better accommodate large and new-type technology companies and their risk-response mechanisms, while keeping pace scientifically. Speaking at the 2026 China Capital Market Academic Annual Meeting, he also called for deepening inclusive and adaptive institutional reforms and improving the listed-company structure by supporting quality firms in new consumption and traditional-industry upgrading.

TREE NEWS update: China Securities Regulatory Commission Chairman Wu Qing said the regulator will further deepen research on long-term market stability mechanisms, speaking at the 2026 China Capital Market Academic Annual Meeting. Wu said China’s capital market is now highly linked with global markets and called for stronger research on cross-border, cross-market and cross-industry risk transmission to guard against abnormal market volatility.

TREE NEWS update: China Securities Regulatory Commission Chairman Wu Qing said the regulator will study and evaluate the optimization of rules on quantitative trading and share reductions, alongside fair and reasonable regulatory arrangements, to protect investor rights. Speaking at the 2026 China Capital Market Academic Annual Meeting, Wu also called for deeper research on improving capital supply structure, growing long-term and patient capital, and reducing market volatility from herd behavior and short-term trading.

TREE NEWS update: China’s National Healthcare Security Administration on Nov. 14 added Jinbeixin (fuxinqibai monoclonal antibody), a Class 1 innovative biologic developed by GenSci, to the national medical insurance drug catalog. The drug, administered once every six months, is used to treat gout. The listing was part of the agency’s announcement of newly added drugs for both the national reimbursement list and the commercial insurance innovative drug list.

TREE NEWS reports: Ether dropped below $1,900, with losses outpacing Bitcoin’s. US spot ether ETFs recorded a sixth consecutive session of net withdrawals, while the next day’s flow tally remained incomplete. The sustained ETF outflows coincide with ether’s decline.

TREE NEWS update: Baili Tianheng’s EGFR×HER3 bispecific antibody-drug conjugate Yizekang (iza-bren) was added to China’s 2026 National Reimbursement Drug List through national price negotiations, the list was announced on November 14 at the 2026 National Innovative Drug High-Quality Development Conference. The drug, the world’s first and only approved EGFR×HER3 bispecific ADC, entered reimbursement in its first year on the market under a new pre-declaration mechanism. The updated list takes effect January 1, 2027.

TREE NEWS update: JW Therapeutics’ CAR-T product Relma-cel (Benlysta) has been added to China’s National Basic Medical Insurance catalog, making it the first and only CAR-T therapy covered, the 2026 Innovative Drug High-Quality Development Conference heard. Industry sources estimate the negotiated price at under 300,000 yuan, with patients’ out-of-pocket cost after reimbursement potentially below 100,000 yuan.

TREE NEWS update: The Securities Association of China has distributed a notice to securities firms launching a survey on financial digitalization applications, aimed at guiding the industry’s deepening of digital finance, improving accounting quality and upgrading financial functions. The questionnaire divides financial digitalization into five progressive stages and focuses on six financial domains, while flagging AI-related risks as a priority to balance efficiency gains with security.

TREE NEWS update: About 147 Shenzhen companies will take part in the 2026 APEC CEO Summit, Shenzhen Mayor Li Yun said at a media briefing on Nov 14 during the APEC Leaders’ Week press center event for Guangdong province and Shenzhen. The firms will meet with domestic and international industry leaders to discuss trade and economic cooperation. The mayor said outcomes from APEC meetings will help Shenzhen deepen economic ties with Asia-Pacific economies.

TREE NEWS update: Shenzhen has become the first city in mainland China to record foreign trade imports and exports exceeding 5 trillion yuan, the city’s commerce bureau chief Zhang Feimeng said on Nov. 14 at a briefing for Chinese and foreign media during the 2026 APEC Leaders’ Meeting Week in Guangdong. Zhang said the latest data show Shenzhen’s foreign trade hitting a new high.

TREE NEWS update: China’s National Healthcare Security Administration said on Nov. 14 that JW Therapeutics’ CAR-T therapy relmacabtagene autoleucel has been added to the national medical insurance catalogue. The drug was priced at 1.29 million yuan per infusion before inclusion. Ma Jun, director of the Harbin Institute of Hematology and Oncology, who took part in the drug’s review and clinical application consensus, said the price has fallen to below 300,000 yuan per infusion after the insurance listing.

TREE NEWS reports: Arca investment chief Jeff Dorman said Vitalik Buterin’s pitch for ether as a store of value is “really misguided,” arguing his math accounts for only about $50 billion of ETH’s value. The remainder is “just social value or hopium,” Dorman said.

TREE NEWS reports: Bitcoin dropped below $67,000 as a broad crypto selloff deepened, with 42 of 44 tokens in a curated watchlist trading lower over 24 hours. Ether’s four-week loss reached 21.4%, reflecting sustained pressure across major digital assets.

TREE NEWS update: China’s 2026 national medical insurance drug catalog and commercial health insurance innovative drug catalog were released in Suzhou, adding 107 drugs, including 51 Class 1 innovative drugs — a record high. The new additions cover oncology, rare diseases, chronic diseases, mental illness and other areas of urgent clinical need. The catalogs set the reimbursement list for the coming year.

TREE NEWS reports: Aave’s governance token AAVE has dropped 30% over the past four weeks, a decline steeper than those of bitcoin and ether, while the protocol’s dollar-denominated locked value fell by a smaller proportion. The token’s losses exceeded those of the two largest cryptocurrencies, even as the value locked in Aave held up better in percentage terms.

TREE NEWS reports: Payward, the parent company of crypto exchange Kraken, reported $487 million in total platform margin for the third quarter, its new headline metric. The figure rose 12% from the second quarter but fell 12% from a year earlier. Unlike Adjusted Revenue, now shown only for comparison, total platform margin excludes the staking rewards Payward pays to clients.